Literature DB >> 18338983

Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.

Toshiaki Suguro1, Takuya Watanabe, Syuusuke Kodate, Gang Xu, Tsutomu Hirano, Mitsuru Adachi, Akira Miyazaki.   

Abstract

Human U-II (urotensin-II), the most potent vasoconstrictor peptide identified to date, is associated with cardiovascular disease. A single nucleotide polymorphism (S89N) in the gene encoding U-II (UTS2) is associated with the onset of Type 2 diabetes and insulin resistance in the Japanese population. In the present study, we have demonstrated a relationship between plasma U-II levels and the progression of diabetic retinopathy and vascular complications in patients with Type 2 diabetes. Eye fundus, IMT (intima-media thickness) and plaque score in the carotid artery, BP (blood pressure), FPG (fasting plasma glucose), HbA(1c) (glycated haemoglobin), U-II, angiogenesis-stimulating factors, such as VEGF (vascular endothelial growth factor) and heregulin-beta(1), and lipid profiles were determined in 64 patients with Type 2 diabetes and 24 non-diabetic controls. FPG, HbA(1c) and VEGF levels were significantly higher in patients with Type 2 diabetes than in non-diabetic controls. Diabetes duration, insufficient glycaemic and BP control, plasma U-II levels, IMT, plaque score and nephropathy grade increased significantly across the subjects as follows: non-diabetic controls, patients with Type 2 diabetes without retinopathy (group N), patients with Type 2 diabetes with simple (background) retinopathy (group A) and patients with Type 2 diabetes with pre-proliferative and proliferative retinopathy (group B). The prevalence of obesity and smoking, age, low-density lipoprotein, triacylglycerols (triglycerides) and heregulin-beta(1) were not significantly different among the four groups. In all subjects, U-II levels were significantly positively correlated with IMT, FPG, and systolic and diastolic BP. Multiple logistic regression analysis revealed that, of the above parameters, U-II levels alone had a significantly independent association with diabetic retinopathy. In conclusion, the results of the present study provide the first evidence that increased plasma U-II levels may be associated with the progression of diabetic retinopathy and carotid atherosclerosis in patients with Type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338983     DOI: 10.1042/CS20080014

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  11 in total

1.  Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?

Authors:  M Demirpence; A Guler; H Yilmaz; A Sayin; Y Pekcevik; H Turkon; A Colak; E M Ari; B Aslanipour; G U Kocabas; M Calan
Journal:  J Endocrinol Invest       Date:  2018-05-26       Impact factor: 4.256

2.  Loss of urotensin II receptor diminishes hyperglycemia and kidney injury in streptozotocin-treated mice.

Authors:  Dieniffer Peixoto-Neves; Praghalathan Kanthakumar; Ravi Kumar; Hitesh Soni; Adebowale Adebiyi
Journal:  J Mol Endocrinol       Date:  2022-03-25       Impact factor: 4.869

3.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Authors:  A M D Watson; M Olukman; C Koulis; Y Tu; D Samijono; D Yuen; C Lee; D J Behm; M E Cooper; K A M Jandeleit-Dahm; A C Calkin; T J Allen
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

4.  Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance.

Authors:  María E Sáez; Tarik Smani; Reposo Ramírez-Lorca; Ignacio Díaz; Manuel Serrano-Ríos; Agustín Ruiz; Antonio Ordoñez
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

5.  NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II.

Authors:  Isabel Diebold; Andreas Petry; Maximilian Burger; John Hess; Agnes Görlach
Journal:  Mol Biol Cell       Date:  2011-09-30       Impact factor: 4.138

6.  Association between the expression of vascular endothelial growth factors and metabolic syndrome or its components: a systematic review and meta-analysis.

Authors:  Mohammad Ishraq Zafar; Kerry Mills; Xiaofeng Ye; Brette Blakely; Jie Min; Wen Kong; Nan Zhang; Luoning Gou; Anita Regmi; Sheng Qing Hu; Juan Zheng; Lu-Lu Chen
Journal:  Diabetol Metab Syndr       Date:  2018-08-03       Impact factor: 3.320

7.  Serum Vascular Endothelial Growth Factor Levels Correlate with Severity of Retinopathy in Diabetic Patients: A Systematic Review and Meta-Analysis.

Authors:  Zhongwei Zhou; Huixiang Ju; Mingzhong Sun; Hongmei Chen
Journal:  Dis Markers       Date:  2019-03-24       Impact factor: 3.434

8.  DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.

Authors:  Vishakha Sharma; Naoe Harafuji; Alexandra Belayew; Yi-Wen Chen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

9.  Urotensin II promotes atherosclerosis in cholesterol-fed rabbits.

Authors:  Yafeng Li; Sihai Zhao; Yanli Wang; Yulong Chen; Yan Lin; Ninghong Zhu; Huadong Zheng; Min Wu; Daxing Cheng; Yandong Li; Liang Bai; Jianglin Fan; Enqi Liu
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

10.  Autocrine Human Urotensin II Enhances Macrophage-Derived Foam Cell Formation in Transgenic Rabbits.

Authors:  Sihai Zhao; Yafeng Li; Shoucui Gao; Xiaojing Wang; Lijing Sun; Daxing Cheng; Liang Bai; Hua Guan; Rong Wang; Jianglin Fan; Enqi Liu
Journal:  Biomed Res Int       Date:  2015-11-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.